HOME PAGE
ABOUT ENEWSCHANNELS
OUR STAFF
Part of the Neotrope News Network


News Desk Columns Books Business Medical Music Software US Govt. RSS
News: Pharma

Pharmaceutical Industry News, Drugs, Nutraceuticals, Vitamins, and Related

CMI’s Mike Mabey to Co-Present with Pfizer Specialty at 2012 PMRG Annual National Conference
Thu, 08 Mar 2012 08:47:39 -0400 EDT
Edited by

ATLANTA, Ga. /eNewsChannels/ — CMI’s Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer (NYSE:PFE), will present ‘Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies’ at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.

E’shee Clinical Esthetic announce Elixir of Life KI Therapy Serum
Tue, 21 Feb 2012 01:58:22 -0400 EDT
Edited by

PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic announced this week a new addition to its product line of skin serums – Elixir of Life KI Therapy Serum – designed to deliver ultimate skin rejuvenation.

Highland Ophthalmology Associates Offers ProKera to Corneal Patients
Tue, 14 Feb 2012 02:59:03 -0400 EDT
Edited by

NEW WINDSOR, N.Y. /eNewsChannels/ — Mary Davidian, M.D., of Highland Ophthalmology Associates, a leading eye surgeon in The Hudson Valley, announces offering her patients a unique corneal wound repair and healing device called ProKera(R). Today, ProKera(R) is the only medical device that can provide wound healing to patients afflicted with a damaged cornea, the outer transparent surface of the eye.

Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy
Wed, 08 Feb 2012 10:54:08 -0400 EDT
Edited by

AUSTIN, Texas /eNewsChannels/ — Bio-Medical Services has received USDA approval and is now offering ACTT(TM) – allergy drop immunotherapy – as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012.

Reaction Biology today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain
Sun, 30 Oct 2011 22:57:54 -0400 EDT
Edited by

MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

Soy Labs, LLC and the Missouri Plant Science Center to spur innovation and economic development in Missouri
Tue, 20 Sep 2011 01:59:33 -0400 EDT
Edited by

MEXICO, Mo. /eNewsChannels/ — Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act.

E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream
Wed, 03 Aug 2011 03:59:36 -0400 EDT
Edited by

PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream – an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies.

City of Scranton, Pa., selects Millennium Administrators, Inc. to Provide Benefit Administration for Active Fire and Police
Tue, 12 Jul 2011 13:45:03 -0400 EDT
Edited by

SCHWENKSVILLE, Pa. /eNewsChannels/ — Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services

ProtiLife Distribution Inc. Launches Health-Focused Online Weight Loss Program for American Women
Thu, 07 Jul 2011 04:59:02 -0400 EDT
Edited by

MONTREAL, Quebec /eNewsChannels/ — ProtiLife Distribution Inc., a leader in the development and distribution of high-quality protein supplements for over 20 years, has launched its online weight loss program to the U.S. market.

Multi-Tier Micro Plate System announced by Laboratory Supply Distributors Corp.
Wed, 04 May 2011 04:58:13 -0400 EDT
Edited by

VINELAND, N.J. /eNewsChannels/ — Designed for analytical research and clinical diagnostic testing, Laboratory Supply Distributors Corp. announces the 96-Well Multi-Tier™ Micro Plate System. Its unique, patented design allows for more flexibility and ease of use.

REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
Mon, 28 Feb 2011 13:53:36 -0400 EDT
Edited by

SAN MARINO, Calif. /eNewsChannels/ — Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

New Strategies and Business & Decision Partner to Bring Industry Leading ERP Solutions to Pharma Industry
Mon, 03 Jan 2011 12:30:56 -0400 EDT
Edited by

PHOENIX, Ariz. /eNewsChannels/ — As a part of Business & Decision’s ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of ‘AX for Pharma’ an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization.

Hormone Therapy and Breast Cancer: Is There a Connection? ask Practitioners from Belvidere Pharmacy and Balancing Health
Thu, 09 Dec 2010 07:00:10 -0400 EDT
Edited by

SOMERSET, N.J. /eNewsChannels/ — From the blogosphere to mainstream media, there’s been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the Oct. 2010 issue of the Journal of the American Medical Association. Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women’s health, examine the issue.

Ethnographer Laura Winn Johnson to Present at PMRG Institute
Tue, 12 Oct 2010 08:28:46 -0400 EDT
Edited by

ATLANTA, Ga. /eNewsChannels/ — CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, Mass., on Oct. 24-26, 2010. The theme for this year’s conference is ‘Navigating Healthcare’s Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.’

Reaction Bio Receives National Cancer Institute Grant for Epigenetic Platform
Wed, 11 Aug 2010 11:54:06 -0400 EDT
Edited by

MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.

Epeius Bio’s Rexin-G® Receives High-tech Validation as Strategic Anti-cancer Agent
Wed, 16 Dec 2009 13:12:02 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus [...]

BIO Investor Forum: Epeius Biotechnologies Investment Opportunity
Wed, 21 Oct 2009 18:23:47 -0400 EDT
Edited by

SAN FRANCISCO, Calif. — Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being [...]

Epeius Biotech Reports Dose-Dependent Efficacy and Survival Benefits, Efficacy of Rexin-G in Metastatic Pancreas Cancer
Thu, 15 Oct 2009 21:23:12 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety [...]

Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
Tue, 13 Oct 2009 12:59:47 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, [...]

Whistleblower Mark Whitacre says ‘The Informant’ Movie is Only Part of the Story
Wed, 16 Sep 2009 17:30:58 -0400 EDT
Edited by

NEW YORK CITY, N.Y. — As Mark Whitacre, COO of Cypress Systems, Inc., walked the red carpet on September 15 during the premiere of “The Informant,” he had something to say: he is NOT the same man who blew the whistle on his employer in [...]

Pharmaceutical eMarketing using Social Media: How to Use It Effectively
Wed, 09 Sep 2009 12:29:44 -0400 EDT
Edited by

NEW YORK, N.Y. — Eularis is announcing the release of its report “How To Harness The Power Of Social Media In Pharmaceutical eMarketing.” This report puts to rest the issues around “can’t,” and shows Pharmaceutical marketers how they can utilize social media networks effectively to [...]

Patented Green Technology is Potential Silver Bullet for Swine Flu and Most Common Infections
Fri, 26 Jun 2009 14:58:41 -0400 EDT
Edited by

FORT LAUDERDALE, Fla. — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. [...]

Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
Wed, 24 Jun 2009 15:42:09 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of [...]

Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Thu, 18 Jun 2009 19:27:16 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, [...]

The World’s Smallest Hero! Epeius Bio’s Rexin-G, Targeted Therapy for Metastatic Cancers
Wed, 10 Jun 2009 12:51:41 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies’ Rexin-G® is the world’s smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army [...]

Eularis Releases Comprehensive Report on Effective Pharmaceutical eMarketing
Thu, 21 May 2009 18:11:32 -0400 EDT
Edited by

NEW YORK, N.Y. — Eularis is announcing the release of an update to its report “Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond.” The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical [...]

Eularis to Hold Pharma Marketing ROI MasterClass in London
Thu, 21 May 2009 16:32:10 -0400 EDT
Edited by

LONDON, U.K. — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing [...]

Epeius’ Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
Thu, 21 May 2009 15:57:22 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid [...]

Hot Rising Fitness Star Natalie Waples Takes On Steroids Issue in Fitness Biz
Mon, 27 Apr 2009 17:14:25 -0400 EDT
Edited by

ORLANDO, Fla. — Natalie Waples is one of the brightest young stars in the fitness firmament. The eye-catching Canadian made her pro debut last season, winning her first professional event at the IFBB North American Figure Championships. She has graced the September ’08 cover of [...]

Cancer-Destroying Biotech: Epeius Bio Launches Rexin-G eBook Tutorial
Mon, 16 Feb 2009 14:00:30 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and [...]

Epeius Bio’s Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemo-Resistant Pancreatic Cancer
Wed, 21 Jan 2009 17:58:21 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated [...]

Silver Safety Committee Gives Guidelines for Safe Use of Any Ionic or Colloidal Silver Supplement
Fri, 09 Jan 2009 16:06:31 -0400 EDT
Edited by

FORT LAUDERDALE, Fla. — The Silver Safety Committee this week announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver. [...]

Epeius Bio Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
Wed, 17 Dec 2008 14:00:46 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. [...]

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Cancers
Fri, 21 Nov 2008 20:08:46 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK [...]

Eularis Analyzes Pre-Launch Brand Planning with New Pharma Industry Report
Tue, 18 Nov 2008 19:17:06 -0400 EDT
Edited by

LONDON, U.K. — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful [...]

Rexin-G Clinical Trials for Pancreatic Cancer and Breast Cancer Open in New York
Sun, 02 Nov 2008 16:05:15 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary [...]

SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)
Sun, 02 Nov 2008 15:56:54 -0400 EDT
Edited by

FRESNO, Calif. — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on [...]

Epeius Biotechnologies Reveals a New Generation of Tools for Medical Gene Delivery
Wed, 08 Oct 2008 15:58:16 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled “Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer [...]

Eularis Releases First-Ever Pharma Study: ROI of Pre-Launch Named Patient Programs
Wed, 17 Sep 2008 14:47:22 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, “Implementing a pre-launch named patient programme – evidence of increased market share,” provides [...]

Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal
Tue, 16 Sep 2008 16:03:47 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie [...]

Eularis Analyzes Most Effective Generics Defense Strategies with New Pharma Industry Report
Mon, 14 Jul 2008 19:08:43 -0400 EDT
Edited by

NEW YORK, N.Y. and TOKYO, JAPAN — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company [...]

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
Thu, 10 Jul 2008 16:52:08 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for [...]

Eularis Challenges Pharma Industry in 2008: Are You Measuring the Wrong Things
Tue, 08 Jul 2008 15:37:20 -0400 EDT
Edited by

LONDON UK, and TOKYO Japan — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, [...]

Intravenous Infusions of Epeius Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity
Tue, 03 Jun 2008 12:47:43 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has [...]

OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies
Fri, 30 May 2008 12:38:36 -0400 EDT
Edited by

RICHMOND, Texas — CYNACON / OCuSOFT (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide. OCuSOFT(R), Inc., [...]

Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
Fri, 30 May 2008 11:49:40 -0400 EDT
Edited by

SAN MARINO, Calif. — ASCO 2008 — Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J [...]

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity
Fri, 23 May 2008 13:02:06 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given [...]

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
Wed, 21 May 2008 20:05:56 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G [...]

Eularis to Address Marketing Return at Japanese Pharma Marketing Excellence Conference
Thu, 15 May 2008 10:51:51 -0400 EDT
Edited by

TOKYO and LONDON, UK — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, [...]

Dr. Andree Bates to Address Pharma Research ROI
Thu, 24 Apr 2008 01:45:51 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation titled, “How to Tell if You Are Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.”

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity
Thu, 24 Apr 2008 00:56:32 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G’s anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G.

Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Advocating Special Type of Selenium
Fri, 18 Apr 2008 18:37:51 -0400 EDT
Edited by

FRESNO, Calif. — Chairman and CEO, Paul Willis stated, “Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company’s chief operating officer and president of operations.” Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium known as SelenoExcell(R).

Patent for Targeted Injectable Gene Delivery In Vivo Awarded to Epeius Biotech
Thu, 27 Mar 2008 21:51:02 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G.

Patient Adherence Exposed in Pharma Industry Report
Fri, 14 Mar 2008 21:17:33 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, “Ensuring Profitable Patient Adherence Programs.”

Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference London
Tue, 11 Mar 2008 22:59:50 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, England — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, “Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?”

Tom Brady, STG Media Tackle Myo-Med Campaign
Fri, 07 Mar 2008 03:17:08 -0400 EDT
Edited by

TEMPE, Ariz. — Superbowl quarterback, Tom Brady has agreed to be the face of Myo-Med, for the launch of their 2008 media campaign. BioForce, the makers of Myo-Med, recently appointed STG Media Corp. as their agency of record to assist them in creating brand awareness among athletes and arthritis sufferers nationwide.

deverus, Inc. Partners with eScreen Inc. to Offer Instant Drug Testing Device
Tue, 08 Jan 2008 00:36:30 -0400 EDT
Edited by

AUSTIN, Texas — deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through eScreen, deverus will now provide clients with technology that creates a web-based system that delivers faster drug test results and paperless transactions.

Epeius Bio Applauds the Belated Scholarship of Their Academic Contemporaries, as Targeted Gene Therapy Comes of Age in 2007
Thu, 20 Dec 2007 22:51:52 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled “In Vivo Barriers to Gene Delivery” was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G
Wed, 19 Dec 2007 22:10:34 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.

Eularis Challenges Pharma Industry: Are You Measuring the Wrong Things?
Tue, 27 Nov 2007 03:23:08 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years. To address this alarming issue, Eularis announces the availability of its new report, “Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?”

FDA Approves the Opening of a Phase II Registration Protocol Using Rexin-G for Osteosarcoma
Wed, 07 Nov 2007 21:47:40 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.

Eularis Releases Update of Its Comprehensive Report on Pharmaceutical Marketing
Thu, 01 Nov 2007 02:21:13 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — Eularis is announcing the release of an update to its report, “Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.” Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.

Garrett Stafford of Detroit Red Wings Endorses Vitamin Supplement, First Step for Energy
Fri, 26 Oct 2007 03:07:58 -0400 EDT
Edited by

LOS ANGELES, Calif. — Full Performance Fitness Inc. has signed a deal with new Detroit Red Wings defenseman Garrett Stafford. Garrett is a Los Angeles native, but played in the northeast growing up. He finished the regular season as the Sharks top scoring defenseman and T-8th among AHL blueliners with 41 points.

Epeius Biotech Leads Keynote on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit
Sat, 20 Oct 2007 01:20:36 -0400 EDT
Edited by

SAN MARINO, Calif. and BOSTON, Mass. — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on “The Advent of Pathotropic Medicine for Cancer” at the Global Pharma R&D Summit 2007 to be held in Boston MA. On October 22, 2007 at 8:00 a.m., Dr. Hall will present the scientific principles, the clinical validation, and global development status.

OCuSOFT Refutes Comparison Time-Kill Study Ad Released by Advanced Vision Research
Sat, 13 Oct 2007 01:40:56 -0400 EDT
Edited by

RICHMOND, Texas — OCuSOFT Inc., producer of the popular ocular-lid hygiene products, OCuSOFT(R) Lid Scrub(TM) and OCuSOFT(R) Lid Scrub(TM) PLUS, is responding to a recent advertisement released by Advanced Vision Research (AVR) that was found to be misleading.

Eularis Announces Expanded Product Offerings, Reshaping Pharmaceutical Analytics
Wed, 26 Sep 2007 20:40:35 -0400 EDT
Edited by

NEW YORK, N.Y. and LONDON, U.K. — Campbell Belman, an established pharmaceutical analytics company, today introduces its new name: Eularis. This announcement reflects the significant growth the Company has achieved across its full range of pharmaceutical analytics products, which have helped tailor the advertising and marketing programs of its global top-tier clients.

Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product
Tue, 07 Aug 2007 19:08:46 -0400 EDT
Edited by

ALODOXRICHMOND, Texas — CYNACON/OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.

Networks Reject ‘alli…Poopy-In-Your-Pants’ Commercial from Rival Diet Pill Distributor, Generix Laboratories
Sat, 16 Jun 2007 00:45:46 -0400 EDT
Edited by

alli accidentSALT LAKE CITY, Utah — Network executives from ABC, NBC and CBS seem to have lost their sense of humor when it came to broadcasting what’s affectionately been dubbed the “alli… Poopy-In-Your-Pants” ad from rival diet pill distributor Generix Labs, makers of Leptopril(TM).

U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas – New Clintelligence(R) Alignment Module Advances Global Management
Fri, 15 Jun 2007 20:07:16 -0400 EDT
Edited by

KENILWORTH, N.J. — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Wed, 06 Jun 2007 19:12:08 -0400 EDT
Edited by

Epeius BiotechSAN MARINO, Calif. — Epeius Biotechnologies announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour – published in the June issue of the International Journal of Oncology, documents the histologic features of tumor destruction observed in chemo-resistant cancers.

Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials for Breast Cancer and Sarcoma
Wed, 06 Jun 2007 01:30:05 -0400 EDT
Edited by

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at Biotech Conferences
Thu, 17 May 2007 02:33:24 -0400 EDT
Edited by

Epeius BiotechSAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company’s innovative tumor-targeting technology embodied in its lead product, Rexin-G, the first targeted genetic medicine developed to treat metastatic cancer.

Local Pharmacy is First in New Jersey to Earn Top Quality & Safety Endorsement
Wed, 16 May 2007 01:23:02 -0400 EDT
Edited by

WASHINGTON, D.C. — Belvidere Pharmacy is the first pharmacy in the state of New Jersey to earn the Pharmacy Compounding Accreditation Board’s Seal of Accreditation – a new system of standards created by some of the leading organizations in pharmacy. The accreditation demonstrates that Belvidere Pharmacy meets the highest quality and safety standards in its profession.

Pharmaceutical Giants Take Aim at Tightening Productivity in Research and Development Using State-of-the Art Business Intelligence Tools
Fri, 04 May 2007 03:04:01 -0400 EDT
Edited by

KENILWORTH, N.J. — 3C Company, Inc. (www.3cpharma.com), a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence – 3C Company’s Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio.

Libutol™ All Natural ‘Feel Good’ Pill Strikes a Chord with Millions of Women
Fri, 27 Apr 2007 19:34:33 -0400 EDT
Edited by

LibutolSALT LAKE CITY, Utah — If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts (and women themselves) are willing to admit. That’s the logical conclusion drawn from the phenomenal reaction women are having to Libutol, “The Little Yellow Pill That Makes Life Better” from Blackett Pharmacal.

Campbell Belman Releases Comprehensive Report for Pharmaceutical Marketers
Thu, 22 Feb 2007 02:04:57 -0400 EDT
Edited by

Campbell BelmanNEW YORK, N.Y. — Campbell Belman’s mission is to remove the uncertainty about marketing return-on-investment (ROI) for pharmaceutical companies; a new comprehensive report releases proven approaches for real and measurable results. The pharmaceutical environment is turbulent, and what used to work to create an industry wide growth of 20 percent, no longer does.

Stauber Names Jim Freeman as Director of Sales and Marketing
Mon, 11 Sep 2006 20:57:18 -0400 EDT
Edited by

FULLERTON, Calif. — Stauber Performance Ingredients, Inc., announced today the appointment of Jim Freeman to the position of Director of Sales and Marketing. The position reports to John Milazzo, President of Stauber, and became effective on August 30, 2006.


 
eNewsChannels Categories:
Popular Topics by Content and Search
Neotrope®
News Network